



**JAGSONPAL PHARMACEUTICALS LIMITED**

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24  
CIN No. L74899DLI978PLC009181

JPL/SEC/STOCK-CORR-2013	Date : August 14th, 2017
The National Stock Exchange of India Ltd. Exchange Plaza, Kamala Mills Compound Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	The Manager - Listing The Bombay Stock Exchange Ltd. Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
<b>CM Quote : JAGSNPHARM</b>	<b>Script Code 507789</b>
<b>Subject : RECTIFIED RESULTS IN IND AS FORMAT</b>	



Sir/Madam,

We herewith enclose the PDF format of rectified results as per Ids As format.

Kindly take the same on records.

Thanking you,

Yours faithfully,  
For **JAGSONPAL PHARMACEUTICALS LTD.**

  
  
**(R. K. KAPOOR)**  
**COMPANY SECRETARY.**



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

Statement of Standalone Unaudited Financial Results for the Quarter ended 30.06.2017

PART-I Particulars	3 months ended 30.06.2017 Unaudited	3 months ended 31.03.2017 Audited	3 months ended 30.06.2016 Unaudited
<b>1 Income from operations</b>			
a Gross Sales/Revenue from Operations	2696.78	2977.67	4019.54
b Other Operating Income	0	11.87	13.15
<b>Total Income from operations</b>	<b>2696.78</b>	<b>2989.54</b>	<b>4032.69</b>
<b>2 Other Income</b>	<b>12.15</b>	<b>7.72</b>	<b>0.03</b>
<b>3 Total Income [ 1+2]</b>	<b>2708.93</b>	<b>2997.26</b>	<b>4032.72</b>
<b>4 Expenses</b>			
a Cost of materials consumed	1803.09	1031.85	1673.90
b Purchases of stock-in-trade	425.42	527.31	374.99
c Changes in inventories of finished goods, work in progress and Stock in trade	-826.45	-690.23	-422.43
d Excise Duty	7.13	41.78	8.52
e Employee benefits expenses	958.66	999.78	1116.11
f Finance Cost	18.83	23.42	94.87
g Depreciation and amortisation expense	26.47	22.88	70.43
h Other expenses	718.05	1030.73	1036.16
<b>Total expenses</b>	<b>3131.00</b>	<b>2987.52</b>	<b>3952.55</b>
<b>5 Profit before exceptional items and taxes (3-4)</b>	<b>-422.07</b>	<b>9.74</b>	<b>80.17</b>
6 Exceptional Items	0.00	0.00	0.00
<b>7 Profit before tax [5-6]</b>	<b>-422.07</b>	<b>9.74</b>	<b>80.17</b>
8 Tax expense	0.00	-71.84	16.03
<b>9 Net Profit for the period [7-8]</b>	<b>-422.07</b>	<b>81.58</b>	<b>64.14</b>
10 Other Comprehensive Income			
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00
<b>11 Total Other Comprehensive Income [A(i) + A(ii)]</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>12 Total Comprehensive Income [9+11]</b>	<b>-422.07</b>	<b>81.58</b>	<b>64.14</b>
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90
<b>14 Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)</b>			
a. Basic (Rs.)	-1.61	0.31	0.24
b. Diluted (Rs.)	-1.61	0.31	0.24

**Notes**

- 1) The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 14, 2017.
- 2) The Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- 3) Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- 4) The above results are available on website of the company www.jagsonpal.com.
- 5) These unaudited financial results have been subjected to limited review by the Statutory Auditors of the Company who have expressed an unqualified / unmodified conclusion on these results.
- 6) The Company has adopted Indian Accounting Standards (referred to as 'Ind AS') with effect from 1st April 17 and accordingly these financial results alongwith the comparatives have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 on 'Interim Financial Reporting' as prescribed under section 133 of the Companies ACT, 2013 and read with relevant rules issued thereunder and other accounting standards generally accepted in India.
- 7) Reconciliation between results previously reported under erstwhile Indian GAAP and as presented now under Ind AS are given below:-

Particulars	Quarter ended 30.06.2016	Year to date ended 30.06.2016
Net Profit for the period as per Indian GAAP	64.14	64.14
Adjustments :		
Net Profit for the period as per Ind AS	64.14	64.14
<b>Total Comprehensive Income as per Ind AS</b>	<b>64.14</b>	<b>64.14</b>

- 8) The Ind AS compliant comparative figures for the quarter ended June 30, 2016 and Year to date June 30, 2016 have not been subjected to review or audit. However, the company's management has exercised necessary due diligence to ensure that such financial results provide true and fair view of its affairs.



By Order of the Board  
For Jagsonpal Pharmaceuticals Limited

*Rajpal Singh Kohita*  
Managing Director

Factory : 20 K.M. Main Road, New Delhi, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-11-26494519-24, 2275952, 2275953  
Date : 14.08.2017

DIN No 00059492

Review Report to Members of Jagsonpal Pharmaceuticals Limited, New Delhi.


We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 30.06.2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For P.P. Thukral & Co.  
Chartered Accountants

  
SURESH SETHI

Partner

Place : New Delhi  
Date: 14.08.2017

Firm's Registration Number: 000632N  
Membership No. : 089318



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DLI978PLC009181

JPL/SEC/STOCK-CORR-2013	Date : August 14th, 2017
The National Stock Exchange of India Ltd. Exchange Plaza, Kamala Mills Compound Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	The Manager - Listing The Bombay Stock Exchange Ltd. Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
<b>CM Quote : JAGSNPHARM</b>	
<b>Subject : Declaration Under Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</b>	

Sir,

Pursuant to regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We declare that the Auditors Limited Review for quarter ended 30.06.2017 given by Statutory Auditors is clean and does not have any qualification or reservation and no figure have been modified / adjusted.

Please take on records.

Thanking you,

Yours faithfully,  
For JAGSONPAL PHARMACEUTICALS LTD.

(R. K. KAPOOR)  
COMPANY SECRETARY

